The approval of the non-adjuvanted bivalent respiratory syncytial virus prefusion F (RSVpreF) protein subunit vaccine for pregnant people in the course of the 2023-2024 RSV season marked a big step in maternal and neonatal well being. Medical knowledge on its security and perinatal outcomes have been sparse on the time, nevertheless, a retrospective observational cohort examine performed at two New York Metropolis hospitals sought to bridge this data hole by evaluating the affiliation between prenatal RSVpreF vaccination standing and numerous maternal and neonatal outcomes. Outcomes have been revealed within the Journal of the American Medical Association.
This examine included 2973 eligible pregnant girls who delivered singleton gestations at 32 weeks’ gestation or later between September 22, 2023, and January 31, 2024. The median age of members was 34.9 years.
Within the cohort, 34.5% had digital well being report proof of RSVpreF vaccination earlier than supply, a considerably greater charge than the nationwide common of 17.8% reported by the CDC. The imply gestational age at vaccination was 34.5 weeks. The examine discovered no vital affiliation between prenatal RSVpreF vaccination and elevated danger of preterm beginning (PTB), outlined as supply earlier than 37 weeks’ gestation.
Along with PTB, the examine examined a number of different maternal and neonatal outcomes. The incidence of hypertensive issues of being pregnant (HDP), small-for-gestational-age (SGA) beginning weight, stillbirth, neonatal intensive care unit (NICU) admission, respiratory misery, jaundice, hypoglycemia, and sepsis have been analyzed. Notably, there was an elevated danger of general HDP within the vaccinated group within the time-dependent mannequin. Nonetheless, no vital variations have been noticed in different outcomes, suggesting the general security of the vaccine throughout being pregnant.
The findings from this examine present crucial real-world proof supporting the protection of the RSVpreF vaccine for pregnant people. Dr. Moeun Son, professor of obstetrics and gynecology at Weill Cornell Drugs and the examine’s lead creator, emphasised to Medical Dialogues, “The true world proof offers a further layer of confidence concerning the security of this vaccine throughout being pregnant.”
In conclusion, this examine offers reassuring proof that prenatal RSVpreF vaccination doesn’t improve the chance of preterm beginning and is usually protected for pregnant people. Whereas an elevated danger of HDP was noticed, additional investigation is important to grasp this affiliation totally.
Sources: Journal of the American Medical Association, Medical Dialogues
Trending Merchandise
